Table 2. Lipid lowering therapy.

	Total (N = 12040)	Male (N = 6860)	Female (N = 5180)
Prior lipid lowering therapy (%)	39.3	39.5	39.0
Statins (%)	37.1	37.5	36.5
Niacin (%)	1.5	1.4	1.7
Fibrates (%)	6.0	6.2	5.8
Monitoring of blood lipid 3 months prior to enrollment (%)	41.3	40.7	42.2
Monitoring of creatine kinase and Liver enzyme 3 months prior to enrollment (%)	30.8	30.9	30.6
Adverse effect (%)	1.5	1.5	1.5
Myalgia (%)	0.3	0.3	0.3
Elevation of Liver enzyme (%)	0.4	0.4	0.4
Elevation of creatine kinase (%)	0.04	0.06	0.02